Stage-dependent nigral neuronal loss in incidental Lewy body and parkinson's disease

Movement Disorders

Volumn 29, Issue 10, 2014, Pages 1244-1251

  Dijkstra, Anke A ^a   Voorn, Pieter ^a   Berendse, Henk W ^a   Groenewegen, Henk J ^a,b   Rozemuller, Annemieke J M ^a,b   van de Berg, Wilma D J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

Braak synuclein staging; Parkinson's disease; Substantia nigra; synuclein

Indexed keywords

ALPHA SYNUCLEIN;

AGED; ARTICLE; AUTOPSY; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEDICAL RECORD; MORPHOMETRICS; NERVE CELL; NETHERLANDS; NIGRAL NEURONAL LOSS; PARKINSON DISEASE; PROTEIN AGGREGATION; QUANTITATIVE STUDY; SUBSTANTIA NIGRA; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CELL COUNT; CELL DEATH; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CELL COUNT; CELL DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NETHERLANDS; NEURONS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; SUBSTANTIA NIGRA;

EID: 84908897412     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25952     Document Type: Article

References (31)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373: 2055-2066.
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alphα-synuclein in Lewy bodies. Nature 1997;388: 839-840.
3. Cookson MR. Alphα-synuclein and neuronal cell death. Mol Neurodegener. 2009;4:9.
4. Luk KC, Kehm V, Carroll J, et al. Pathological alphα-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012;338:949-953.
5. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
6. Kingsbury AE, Bandopadhyay R, Silveira-Moriyama L, et al. Brain stem pathology in Parkinson's disease: an evaluation of the Braak staging model. Mov Disord 2010;25:2508-2515.
7. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alphα-synucleinopathy: relevance in a population-based cohort. Neurology 2008;70:1042-1048.
8. Dickson DW, Fujishiro H, DelleDonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008;115:437-444.
9. Milber JM, Noorigian JV, Morley JF, et al. Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology 2012;79:2307-2314.
10. DelleDonne A, Klos KJ, Fujishiro H, et al. Incidental Lewy body disease and preclinical Parkinson disease. Arch Neurol 2008;65: 1074-1080.
11. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
12. Greffard S, Verny M, Bonnet AM, Seilhean D, Hauw JJ, Duyckaerts C. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death. Neurobiol Aging 2010;31:99-103.
13. Mori F, Nishie M, Kakita A, Yoshimoto M, Takahashi H, Wakabayashi K. Relationship among alphα-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J Neuropathol Exp Neurol 2006;65:808-815.
14. Parkkinen L, O'Sullivan S, Collins C, Petrie A, Holton JL, Revesz T, Lees A. Disentangling the relationship between Lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinson's Dis 2011;1:277-286.
15. AlafuzoffI, Arzberger T, Al-Sarraj S, et al. Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008;18:484-496.
16. AlafuzoffI, Thal DR, Arzberger T, et al. Assessment of betaamyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009;117:309-320.
17. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
18. Paxinos G. Human Brain Stem Atlas. 1995. San Diego, CA: Academic Press.
19. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1991;54:388-396.
20. Hindle JV. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010;39:156-161.
21. Schmitz C, Hof PR. Design-based stereology in neuroscience. Neuroscience 2005;130:813-831.
22. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alphα-synuclein correlates with striatal dopamine deficit. Mov Disord. 2008;23:1608-1612.
23. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132:2947-2957.
24. Frigerio R, Fujishiro H, Ahn TB, et al. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011;32:857-863.
25. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187-204.
26. Buchman AS, Shulman JM, Nag S, et al. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012;71:258-266.
27. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
28. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
29. Schulz-Schaeffer WJ. The synaptic pathology of alphα-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol 2010;120:131-143.
30. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 2006;63:584-588.
31. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010;1184:188-195.